NCT06273748 · Meyer Children's Hospital IRCCS
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
What this study is about
Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases.
View original scientific description
Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In Italy, there is no national or regional registry for non-infectious chronic uveitis as per the Prime Ministerial Decree (DPCM) of March 3, 2017 (Identification of surveillance systems and registries for mortality, tumors, and other diseases). However, many clinical centers adopt data recording systems to evaluate the quality of care and to study diseases and outcomes.
Primary outcome measures
Describe a population of paediatric patients with chronic non-infectious uveitis
Time frame: thorugh the study and after 1 year
* Frequency of each aetiology of uveitis * Frequency of signs and symptoms at onset of uveitis * Frequency of laboratory findings * Frequency of each anatomical subtype of uveitis
Describe a population of paediatric patients with chronic non-infectious uveitis
Time frame: 6 months, 12 months, 2 years and then every year
* Frequency of complications at onset, 6 months, 12 months, 2 years, then every year * Frequency of impaired visual acuity (LogMAR0.4-1) and blindness (LogMAR\>=1) at onset and at different time points (6 months, 12 months, 18 months, 2 years, then every year)
Identify any differences between the different forms of uveitis in terms of characteristics and outcomes
Time frame: thorugh the study and after 1 year
* Frequency of complications and impaired visual acuity * Description of laboratory characteristics
Identify risk factors for a more severe course
Time frame: thorugh the study and after 1 year
Percentages of children with impaired visual acuity * Percentages of children with ocular complications
Frequency achievement of response for each drug according to the definition of response
Time frame: thorugh the study and after 1 year
Frequency achievement of response for each drug according to the definition of response of the MIWGUC group
Time to archieve the response after drug initiation
Time frame: thorugh the study and after 1 year
Time to archieve the response after drug initiation
Achievement of inactive disease on therapy according to the definition of MIWGUC
Time frame: thorugh the study and after 1 year
Achievement of inactive disease on therapy according to the definition of MIWGUC
Time to achieve inactive disease on therapy according to the definition of MIWGUC
Time frame: thorugh the study and after 1 year
Time to achieve inactive disease on therapy according to the definition of MIWGUC
Presence and percentages of flares on therapy after achievement of remission on therapy
Time frame: thorugh the study and after 1 year
Presence and percentages of flares on therapy after achievement of remission on therapy
Time to the first flare on therapy
Time frame: thorugh the study and after 1 year
Time to the first flare on therapy
Time to flare after drug withdrawal
Time frame: 6, 12 and 18 months, 2 years then every year
Time to flare after drug withdrawal * Proportion of Flare after drug withdrawal in general at the last available follow-up * Proportion of children who flared after drug withdrawal at 6, 12 and 18 months, 2 years then every year
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- diagnosis of non-infectious chronic uveitis before the age of 16;
- signed informed consent form.
Exclusion criteria
- Patients with a diagnosis of infectious uveitis
- history of malignant pathology,
- history of demyelinating pathology,
- history of cerebral vasculitis
Where
- Kansas City, Kansas
- Boston, Massachusetts
- Cincinnati, Ohio
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 27, 2026 · Source of record for eligibility and locations